NZE · TRU.NZ · NZD
Stock price, earnings
Quote as of Oct 30, 2026, 02:38 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NZD. Historical prices are not a forecast.
TruScreen Group Limited’s quoted price sits in the lower half of its reported 52-week range, 64.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow TruScreen Group Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TruScreen Group Limited, alongside its subsidiaries, focuses on the development, manufacturing, and global distribution of advanced systems for cancer detection. Their commercial reach extends across various international territories, including Mexico, China, Russia, Vietnam, Zimbabwe, countries within Eastern Europe, the Middle East/North Africa region, and beyond. A flagship product is the TruScreen cervical cancer screening system, a specialized medical device engineered to provide real-time identification of precancerous and cancerous tissue present on the cervix. Established in 2013, the company, with its primary base of operations in Auckland, New Zealand, officially changed its name from TruScreen Limited to Truscreen Group Limited in August 2020.
Latest available per-share figures in NZD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NZ$47.66+NZ$0.28 (+0.59%)
Fisher & Paykel Healthcare Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 3.97% below the high.
NZ$1.77+NZ$0.03 (+1.72%)
Ryman Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
NZ$6.56+NZ$0.06 (+0.92%)
Summerset Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
NZ$4.65-NZ$0.05 (-1.06%)
AFT Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NZ$0.64-NZ$0.01 (-1.54%)
Oceania Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.18% below the high.
NZ$0.24NZ$0.00 (0.0%)
Pacific Edge Limited’s quoted price sits in the lower half of its reported 52-week range, 30.88% below the high.
NZ$1.93-NZ$0.01 (-0.26%)
Green Cross Health Limited’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
A$0.55+A$0.02 (+2.8%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
